|
24 Jan 2023 |
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
|
|
24 Jan 2023 |
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
|
|
24 Jan 2023 |
Carina Biotech Receives FDA “Safe to Proceed” Letter for IND Application for Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy Candidate for Treatment of Advanced Colorectal Cancer
|
|
24 Jan 2023 |
ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma
|
|
23 Jan 2023 |
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
|
|
23 Jan 2023 |
DiscGenics Announces Positive Two-Year Clinical Data from Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease
|
|
23 Jan 2023 |
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
|
|
23 Jan 2023 |
REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients
|
|
23 Jan 2023 |
Neurogene Announces FDA Clearance of IND for NGN-401 Gene Therapy for Children with Rett Syndrome
|
|
21 Jan 2023 |
Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium
|
|
21 Jan 2023 |
ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324
|
|
20 Jan 2023 |
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
|
|
20 Jan 2023 |
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
|
|
20 Jan 2023 |
Stemedica Initiating Phase IIb/III Clinical Trial for Patients with Chronic Ischemic Stroke
|
|
18 Jan 2023 |
Exegenesis Bio Announces FDA Clearance of Investigational New Drug (IND) Application for EXG102-031; A Novel Gene Therapy for the Treatment of neovascular Age-Related Macular Degeneration (nAMD)
|
|
18 Jan 2023 |
Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma
|
|
16 Jan 2023 |
EverImmune launches phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer
|
|
13 Jan 2023 |
Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection
|
|
13 Jan 2023 |
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
|
|
11 Jan 2023 |
Bio4t2 announces first patient infused with CAR-T targeting solid tumors
|
|
11 Jan 2023 |
Genethon Launches Pivotal Clinical Trial of Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease
|
|
10 Jan 2023 |
Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones
|
|
10 Jan 2023 |
Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors
|
|
10 Jan 2023 |
Avenge Bio Announces Dosing of First Patient in Phase 1/2 Clinical Trial Evaluating AVB-001 for the Treatment of Ovarian Cancer
|
|
10 Jan 2023 |
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
|
